申请人:TOA EIYO LTD.
公开号:US10682323B2
公开(公告)日:2020-06-16
Provided is a novel therapeutic agent for glaucoma, which has sGC-activating action. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an effective component, a compound represented by Formula (I-a) or Formula (I-b) and having a Log D value of more than 1.5 and less than 2.5, or a pharmaceutically acceptable salt thereof. [In formulae (I-a) and (I-b), each symbol is as defined in the description.]
本发明提供了一种新型青光眼治疗剂,它具有 sGC 激活作用。一种青光眼治疗剂或眼压降低剂,其有效成分包含由式(I-a)或式(I-b)表示的、对数 D 值大于 1.5 且小于 2.5 的化合物或其药学上可接受的盐。[在式 (I-a) 和 (I-b) 中,各符号如描述中所定义]。